Amlodipine, clopidogrel and CYP3A5 genetic variability: Effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention

Heart

Volumn 98, Issue 18, 2012, Pages 1366-1372

  Park, Kyung Woo ^a   Kang, Jeehoon ^a   Park, Jin Joo ^a   Yang, Han Mo ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 3A5; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACTIVATION; DRUG POTENTIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEART DEATH; HEART INFARCTION; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE RELEASE REACTION; THROMBOSIS;

AGED; AMLODIPINE; ANGIOPLASTY, BALLOON, CORONARY; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; STROKE; TICLOPIDINE;

EID: 84865198262     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301892     Document Type: Article

References (32)

1. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302 :849-57.
2. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
3. Ford NF. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol 2009;49 :506-12.
4. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9.
5. Siasos G, Tousoulis D, Stefanadis C. CYP2C19 genotype and outcomes of clopidogrel treatment. N Engl J Med 2011;364:481-2.
6. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-19.
7. Park KW, Park JJ, Lee SP, et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011;97:641-7.
8. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9. (Pubitemid 36735258)
9. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49. (Pubitemid 36159890)
10. Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 2003;31:938-44. (Pubitemid 36759065)
11. Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-9.
12. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63.
13. Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011;161:605-10.
14. Olesen JB, Gislason GH, Charlot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011;57:409-17.
15. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710. (Pubitemid 350190847)
16. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315-22. (Pubitemid 44047198)
17. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84. (Pubitemid 44918092)
18. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95. (Pubitemid 350123680)
19. Pinto Slottow TL, Waksman R. Overview of the 2006 Food and drug Administration Circulatory system Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv 2007;69:1064-74. (Pubitemid 46900788)
20. Hicks KA, Stockbridge NL, Targum SL, et al. Bleeding Academic Research Consortium consensus report: the Food and Drug Administration perspective. Circulation 2011;123:2664-5.
21. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-66.
22. Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103:920-5.
23. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84:891-6.
24. Mackenzie IS, Coughtrie MW, MacDonald TM, et al. Antiplatelet drug interactions. J Intern Med 2010;268:516-29.
25. Wrighton SA, Schuetz EG, Thummel KE, et al. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000; 32:339-61. (Pubitemid 32001911)
26. Kuehl P, Zhang J, Lin Y, et al . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91. (Pubitemid 32268418)
27. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41 :89-295.
28. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002;12:331-4. (Pubitemid 34620661)
29. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002;30:1491-6.
30. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9. (Pubitemid 33151512)
31. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005;6:19.
32. http://www.hapmap.org (accessed 7 May 2012).